Comparison of the efficacy of tigecycline and teicoplanin in an experimental methicillin-resistant Staphylococcus aureus osteomyelitis model

Journal of Chemotherapy

Volumn 20, Issue 1, 2008, Pages 53-57

  Kandemir, Özlem ^a,c   Oztuna, V ^a   Colak, M ^a   Akdag, A ^a   Camdeviren, H ^b  

^a MERSIN UNIVERSITY   (Turkey)

^b Zonguldak Karaelmas University School of Medicine   (Turkey)

^c MERSIN UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

MRSA; Osteomyelitis; Tigecycline

Indexed keywords

TEICOPLANIN; TIGECYCLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIUM CULTURE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; OSTEOMYELITIS; RAT; TIBIA;

EID: 41149126084     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.1.53     Document Type: Article

References (25)

1. Parsons B, Strauss E. Surgical management of chronic osteomyelitis. Am J Surg 2004; 188: 57-66.
2. Götz F. Staphylococci in colonization and disease: prospective targets for drugs and vaccines. Curr Opin Microbiol 2004; 7: 477-87.
3. Moreno P, Concia E, Andreoni M, Suter F, Cruciani M. Treatment of bone and soft tissue infections with teicoplanin. J Antimicrob Chemother 1990; 25(3): 435-39.
4. Hamilton-Miller JM. Vancomycin-resistant Staphylococcus aureus: a real and present danger? Infection 2002; 30:118-24.
5. Patel R, Piper KE, Rouse MS, Steckelberg JM. Linezolid therapy of Staphylococcus aureus experimental osteomyelitis. Antimicrob Agents Chemother 2000;44:3438-40.
6. Kasbekar N. Tigecycline: A new glycylcycline antimicrobial agent. Am J Health Syst Pharm. 2006; 63:1235-43.
7. Wilcox MH. Efficacy of tigecycline in complicated skin and skin structure infections and complicated intra-abdominal infections. J Chemother 2005; 17 Suppl 1:23-29
8. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6, sixth edition, vol. 23. National Committee for Clinical Laboratory Standards, Wayne, Pa.
9. Baron EJ, Peterson LR, Finegold SM: Diagnostic Microbiology. Baltimore, Mosby 1994: 284-95.
10. Cremieux AC, Carbon C. Experimental models of bone and prosthetic joint infection. Clin Infect Dis 1997; 25: 1295-1302.
11. Heinz SA, Sakamoto H, Flock JI, et al. Development and characterization of a new model of hematogenous osteomyelitis in the rat. J Infect Dis 1995;171: 1230-36.
12. Andes W, Craig WA. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 2002;19:261-68.
13. Norden CW. Lessons learned from animal models of osteomyelitis. Rev Infect Dis 1988;10:103-110.
14. Tunney MM, Ramage G, Patrick S, Nixon JR, Murphy PG, Gorman SP. Antimicrobial susceptibility of bacteria isolated from orthopaedic implants following revision hip surgery. Antimicrob Agents Chemother 1998; 42: 3002-5.
15. LeForck J, Ristuccia A. Teicoplanin in the treatment of bone and joint infections: An open study. J Infect Chemother 1999; 5: 32-9.
16. Schaison G, Graninger W, Bouza E. Teicoplanin in the treatment of serious infection. J Chemother 2000; 12 suppl 5; 26-33.
17. Anonymous. Vancomycin-resistance Staphylococcus aureus New York, 2004. MMWR Morb Mort Wkly Rep 2004; 53:322-23.
18. Chang S, Sievert DM, Hageman JC et al. Infection with vancomycin-resistant Staphylococcus aureus containing the van A resistance gene. New Engl J Med 2003; 348: 1342-7.
19. Bozdogan B, Esel D, Whitener C, et al. Antibacterial susceptibility of a vancomycin-resistant Stapylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother 2004; 52:864-68.
20. Harwood PJ, Talbot C, Dimoutsos M, Sunderland G, Shaw D, Wilcox MH, Giannoudis PV. Early experience with linezolid for infections in orthopaedics. Injury 2006; 37: 818-26.
21. Aneziokoro CO, Cannon JP, Pachucki CT, Lentino JR. The effectiveness and safety of oral linezolid for the primary and secondary treatment of osteomyelitis. J Chemother 2005; 17: 643-50.
22. Garrison MW, Neumiller JJ, Setter SM. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms. Clin Ther 2005; 27: 12-22.
23. Nathwani D. Tigecycline: clinical evidence and formulary positioning. Int J Antimicrob Agents 2005; 25: 185-92.
24. Ellis-Grosse EJ, Babinchak T, Dartois N et al. The efficacy and safety of tigecycline in the treatment of skin and skin structure infections: results of 2 double -blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41 (Suppl 5): 341-53.
25. Yin LY, Lazzarini L, Li F, Stevens CM, Calhoun JH. Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model. J Antimicrob Chemother. 2005; 55: 995-1002.